Vivus vexed by birth defects with Qnexa component
This article was originally published in Scrip
Executive Summary
Although analysts were not too vexed by the top-line results of a retrospective study that showed a higher numerical rate of oral cleft in children of women exposed during the first trimester of pregnancy to topiramate – one of the two active ingredients in Vivus' experimental weight-loss pill Qnexa (phentermine/topiramate) – investors were on the run during 22 December trading.